A Phase II Randomized Trial with a Modified Dose and Schedule of Subcutaneously Administered Azacitidine and Erythropoietin versus Azacitidine Alone in Patients with Low-Risk Myelodysplastic Syndromes (Less than 11% Marrow and Peripheral Blood Blasts)